ATE454144T1 - Behandlung von malignen neoplasien - Google Patents

Behandlung von malignen neoplasien

Info

Publication number
ATE454144T1
ATE454144T1 AT06829145T AT06829145T ATE454144T1 AT E454144 T1 ATE454144 T1 AT E454144T1 AT 06829145 T AT06829145 T AT 06829145T AT 06829145 T AT06829145 T AT 06829145T AT E454144 T1 ATE454144 T1 AT E454144T1
Authority
AT
Austria
Prior art keywords
treatment
iodo
phenylalanine
malignant neoplasia
pharmaceutical composition
Prior art date
Application number
AT06829145T
Other languages
English (en)
Inventor
Samuel Samnick
Original Assignee
Samuel Samnick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samuel Samnick filed Critical Samuel Samnick
Application granted granted Critical
Publication of ATE454144T1 publication Critical patent/ATE454144T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Soft Magnetic Materials (AREA)
AT06829145T 2005-11-25 2006-11-27 Behandlung von malignen neoplasien ATE454144T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05025776 2005-11-25
PCT/EP2006/011367 WO2007060011A1 (en) 2005-11-25 2006-11-27 Therapy of malignant neoplasias

Publications (1)

Publication Number Publication Date
ATE454144T1 true ATE454144T1 (de) 2010-01-15

Family

ID=37744207

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06829145T ATE454144T1 (de) 2005-11-25 2006-11-27 Behandlung von malignen neoplasien

Country Status (15)

Country Link
US (1) US8268888B2 (de)
EP (1) EP1962822B1 (de)
JP (1) JP5108781B2 (de)
KR (1) KR20080074193A (de)
AT (1) ATE454144T1 (de)
AU (1) AU2006316781B2 (de)
CA (1) CA2630848C (de)
DE (1) DE602006011650D1 (de)
DK (1) DK1962822T3 (de)
ES (1) ES2341575T3 (de)
IL (1) IL191690A (de)
NZ (1) NZ568367A (de)
PL (1) PL1962822T3 (de)
PT (1) PT1962822E (de)
WO (1) WO2007060011A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948154C (en) 2014-05-07 2017-09-26 The University Of Akron Radioopaque, iodine functionalized phenylalanine-based poly(ester urea)s
WO2025202716A1 (en) * 2024-03-26 2025-10-02 Telix Pharmaceuticals (Innovations) Pty Ltd Combination therapy for treating glioblastomas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5816999A (en) * 1997-07-24 1998-10-06 Bischoff; Jeffrey Flexible catheter for the delivery of ionizing radiation to the interior of a living body
WO2000033891A1 (en) * 1998-12-04 2000-06-15 Medivas, Llc Methods for detection of vulnerable plaques using a detectable lipid-avid agent
AU2003299565A1 (en) * 2002-11-27 2004-06-23 Board Of Regents, The University Of Texas System Radiopharmaceuticals and radioactive microspheres for locoregional ablation of abnormal tissues

Also Published As

Publication number Publication date
DE602006011650D1 (de) 2010-02-25
CA2630848C (en) 2014-10-07
PT1962822E (pt) 2010-04-09
ES2341575T3 (es) 2010-06-22
IL191690A (en) 2011-10-31
AU2006316781A1 (en) 2007-05-31
JP5108781B2 (ja) 2012-12-26
AU2006316781B2 (en) 2012-06-14
CA2630848A1 (en) 2007-05-31
KR20080074193A (ko) 2008-08-12
JP2009517356A (ja) 2009-04-30
EP1962822B1 (de) 2010-01-06
EP1962822A1 (de) 2008-09-03
IL191690A0 (en) 2009-08-03
US8268888B2 (en) 2012-09-18
PL1962822T3 (pl) 2010-07-30
US20100003268A1 (en) 2010-01-07
DK1962822T3 (da) 2010-05-17
WO2007060011A1 (en) 2007-05-31
NZ568367A (en) 2010-11-26

Similar Documents

Publication Publication Date Title
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
TW200716646A (en) (S)-N-methylnaltrexone
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA200601776A1 (ru) Метадоновые композиции местного действия и способы их применения
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
GEP20125565B (en) Lactam compounds and their pharmaceutical use
EA201001639A1 (ru) Композиции и способы их получения и применения
SE0301700D0 (sv) Novel compounds
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
TW200606162A (en) Pyrazolopyridine derivatives
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
ATE448232T1 (de) Substituierte heterozyklen
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
CY1115961T1 (el) Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate)
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
ATE466841T1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
EA201000141A1 (ru) Новые триазены для лечения рака
EA200501301A1 (ru) Ментоловые растворы лекарственных препаратов
SE0300457D0 (sv) Novel compounds
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DE602006011650D1 (de) Behandlung von malignen neoplasien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1962822

Country of ref document: EP